Month: May 2022

On Track for Several Milestones in 2022, and Supported by Strong Balance Sheet from Upsized Initial Public OfferingContinued Progress Advancing Epetraborole Clinical Program with Enrollment for Pivotal Phase 2/3 Trial in Treatment-Refractory MAC Lung Disease Expected to Begin in First Half of 2022AN2 Board Strengthened through Appointment of Key Industry ExecutivesMENLO PARK, Calif., May 10, 2022 (GLOBE NEWSWIRE) — AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended March 31, 2022. “Over the past several months, we made significant progress on many key initiatives, executed a successful upsized IPO, strengthened our board with new...

– Strong Start to 2022 with 10% Revenue Growth, 13% Adjusted EBITDA Growth, and Record Backlog – – Completed Strategic Acquisitions of TranSmart Technologies and 1 Alliance Geomatics – – Reaffirms 2022 Outlook for Revenue and Adjusted EBITDA – AUSTIN, Texas, May 10, 2022 (GLOBE NEWSWIRE) — Atlas Technical Consultants, Inc. (Nasdaq: ATCX) (“Atlas” or the “Company”), a leading infrastructure and environmental services provider, announced today results for the first quarter ended April 1, 2022. First Quarter 2022 Highlights:(all comparisons versus the prior-year period unless otherwise noted)Gross revenue grew 9.7% to $135.2 million, driven by 6% organic growth and the contribution from acquisitions. Net loss was $4.4 million. Adjusted net income (2) was $0.9 million, or $0.02 per share, which...

Revenue of $776 million in the First Quarter, up 7% Year-over-Year Core Revenue Grew 9% to $735 million Quarterly Cash Flow From Operating Activities of $65 millionSAN ANTONIO, May 10, 2022 (GLOBE NEWSWIRE) — Rackspace Technology, Inc. (Nasdaq: RXT), a leading end-to-end multicloud technology solutions company, today announced results for its first quarter ended March 31, 2022. Kevin Jones, Chief Executive Officer, commented, “Rackspace Technology benefits from secular tailwinds in a cloud market that shows no signs of slowing. In the first quarter alone, our cloud hyperscaler partners added $10 billion of new cloud revenue. All of this new cloud revenue represents customers moving to the cloud, grappling with change, and needing help on their journey. And Rackspace Technology is extremely well-positioned to be their partner...

CALGARY, Alberta, May 10, 2022 (GLOBE NEWSWIRE) — Freehold Royalties Ltd. (Freehold or the Company) (TSX:FRU) announces first quarter results for the period ended March 31, 2022. Operating and Financial Highlights  Three Months Ended March 31 Three Months Ended December 31FINANCIAL ($ millions, except as noted) 2022   2021   Change 2021   ChangeFunds from operations 71.9   32.4   122 % 68.7   5 %Funds from operations per share, basic ($) (1) 0.48   0.25   92 % 0.46   4 %Acquisitions and related expenditures 1.3   79.8   nm   67.9   nm  Dividends paid per share ($) (2) 0.18   0.06   200 % 0.16   13 %Payout ratio (%) (3) 38 % 24 % 14 % 35 % 3 %Net debt 62.6   64.8   (3 %) 101.2   (38 %)OPERATING          Total production (boe/d) (4) 13,676   10,944   25 % 14,005   (2 %)Oil and NGL (%) 60 % 54 % 6 % 59 % 1 %Petroleum...

TP-03 for the treatment of Demodex blepharitis met all endpoints in the Saturn-2 Phase 3 trial; anticipated NDA submission in the second half of this year Cash runway expected into at least 2026 IRVINE, Calif., May 10, 2022 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for eye diseases, today announced financial results for the first quarter ended March 31, 2022, and recent business achievements. “In the first quarter, we took important steps towards becoming a leading eye care pharmaceutical company. We reported strong and consistent Saturn-2 data, further validating the safety and efficacy of TP-03 and positioning it as the definitive standard of care for millions of patients who suffer from Demodex...

– STS101 SUMMIT Phase 3 efficacy trial enrollment ongoing and on track to read out topline results in Q4 2022 – – New Drug Application (NDA) submission anticipated in Q1 2023 – – $80.6 million in cash, cash equivalents and marketable securities as of March 31, 2022, provides runway into second half of 2023 – SOUTH SAN FRANCISCO, Calif., May 10, 2022 (GLOBE NEWSWIRE) — Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today reported financial results for the first quarter of 2022 and summarized recent business highlights. “We are pleased to report continued progress during the first quarter as we advance toward...

InteliSwab® revenue of $22.1 million in Q1, up 50% sequentially with significant scaling in production Non-COVID molecular kits increase 42% year-over-year demonstrating continued strong growth Management to Host Analyst/Investor Call and Webcast Today at 5:00 p.m. ET BETHLEHEM, Pa., May 10, 2022 (GLOBE NEWSWIRE) — OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced its financial results for the three months ended March 31, 2022. “We made significant progress in the quarter scaling InteliSwab® production and improving the efficiency of our manufacturing process as we look to drive profitable growth,” said OraSure Interim President and CEO Nancy J. Gagliano, M.D., MBA. “Excluding COVID-19 products,...

Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO, Calif., May 10, 2022 (GLOBE NEWSWIRE) — Tricida, Inc. (Nasdaq: TCDA) announced today financial results for the three months ended March 31, 2022 and provided an update on key initiatives. Business UpdateTricida continued to execute on the conduct of the VALOR-CKD renal outcomes clinical trial. Enrollment of patients in the VALOR-CKD trial was completed at the end of 2021 with 1,480 subjects randomized. As of May 9, 2022, randomized subjects had an average treatment duration of approximately 25 months, and the trial had accrued 233 subjects with positively adjudicated primary endpoint events, defined as renal death, end-stage renal disease (ESRD), or greater than or equal to 40% reduction in estimated glomerular filtration rate (eGFR).Upcoming MilestoneTricida previously...

Plans to present data at multiple scientific conferences in 2022, starting with AACR and ASGCT Q1 2022 cash position of $657.4 million Expect to file INDs this year for ex vivo hypoimmune allogeneic CAR T and in vivo fusogen CAR T SEATTLE, May 10, 2022 (GLOBE NEWSWIRE) — Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today reported financial results and business highlights for the first quarter 2022. “In the first quarter, we made significant progress in moving toward clinical trials for programs across our multiple platforms including the ex vivo hypoimmune allogeneic CAR T (SC291) and in vivo fusogen CAR T (SG295) programs, and we remain on track to file INDs for both of these programs this year,” said Steve Harr, Sana’s President and Chief Executive Officer....